Sorry, you need to enable JavaScript to visit this website.
Skip to main content
  • News
    • Press Releases
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • Country List
SEARCH
Home

Main navigation

  • Our Company
    • About Incyte Belgium and Luxembourg
  • What We Do
    • Global Portfolio
    • Hematology and Oncology
    • Inflammation and Autoimmunity
    • Our Medicines
    • Partnerships
  • Culture & Careers
  • HCP Resources
  1. Home
  2. What We Do
  3. Our Medicines
  • SEARCH
  • Our Company
    • About Incyte Belgium and Luxembourg
  • What We Do
    • Global Portfolio
    • Hematology and Oncology
    • Inflammation and Autoimmunity
    • Our Medicines
    • Partnerships
  • Culture & Careers
  • HCP Resources
  • News
    • Press Releases
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • United States

INCYTE AROUND THE WORLD

GLOBAL HEADQUARTERS

DENMARK

ITALY

PORTUGAL

UNITED KINGDOM

AUSTRIA

FINLAND

JAPAN

SPAIN

BELGIUM

FRANCE

THE NETHERLANDS

SWEDEN

CANADA

GERMANY

NORWAY

SWITZERLAND

Close

Interior of a lab
Interior of a lab
Interior of a lab

Our Medicines

  • Hematology - Oncology Therapies

FOR HEALTHCARE PROFESSIONALS

Image of logo for Iclusig(registered trademark) (ponatinib)

Learn more about Iclusig® 
(ponatinib)

FOR HCPS
Image of Pemazyre(registered trademark) (pemigatinib) tablets - 13.5mg, 9mg, 4.5 mg

Learn more about Pemazyre® (pemigatinib)

FOR HCPS
Image of logo for MINJUVI(registered trademark) (tafasitamab-cxix) 200mg - for injection, for intravenous use

Learn more about Minjuvi® 
(tafasitamab)

FOR HCPS
Opzelura® (ruxolitinib) cream

Learn more about Opzelura® 
(ruxolitinib) cream

FOR HCPS

Our Global Portfolio

HCP Resources
Footer Logo
  • LinkedIn Icon
  • Twitter Icon
  • Instagram Icon
  • Facebook Icon
  • Youtube Icon
  • Our Company
    • About Incyte Belgium and Luxembourg
  • What We Do
    • Global Portfolio
    • Hematology and Oncology
    • Inflammation and Autoimmunity
    • Our Medicines
    • Partnerships
  • Culture & Careers
  • HCP Resources
  • News
    • Press Releases
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • Legal Notice
  • Suppliers
  • Site Map
  • Privacy Policy
  • Cookie Policy
July 2024 BE/CORP/NP/24/0001© 2012-2026 Incyte.